Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 20/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 19/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2793 | 0.89 | SLC6A4 (0.57) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL2111 | 0.82 | SLC6A4 (0.48) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL9118545 | 0.79 | SLC6A4 (0.61) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL1923 | 0.78 | CTSL (0.37) | SLC6A3SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL2242 | 0.78 | SLC6A4 (0.60) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL9116253 | 0.77 | HDAC4 (0.36) | SLC6A3SLC6A4 | |
| SCHEMBL10981709 | 0.75 | SLC6A4 (0.73) | SLC6A3SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL2049 | 0.74 | SLC6A4 (0.71) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL1822 | 0.70 | SLC6A4 (0.63) | SLC6A3SLC6A4SLC6A2 | |
| Maleic Acid SCHEMBL10838420 | 0.69 | SLC6A4 (0.48) | SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9931346-B2 | Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-04-03 | — | — | US | disclosed |
| US-20160310500-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-10-27 | — | — | US | disclosed |
| EP-3082782-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015091508-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-06-25 | — | — | WO | disclosed |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-12-27 | — | — | US | disclosed |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-09-06 | — | — | US | disclosed |
| US-20070196421-A1 | Soft tissue implants and drug combination compositions, and use thereof | ANGIOTECH INTERNATIONAL AG (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070198063-A1 | Electrical devices and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| US-20070197957-A1 | Implantable sensors, implantable pumps and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| WO-2007041584-A2 | IMPLANTABLE SENSORS, IMPLANTABLE PUMPS, AND ANTI-SCARRING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| EP-1036147-A1 | CLEAR OR TRANSLUCENT AQUEOUS FABRIC SOFTENER COMPOSITIONS CONTAINING HIGH ELECTROLYTE CONTENT AND OPTIONAL PHASE STABILIZER | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-20 | — | — | EP | disclosed |
| EP-0989895-A1 | PROCESS FOR IMPROVING THE ODOR OF COMMERCIAL SOLVENT USED IN FABRIC SOFTENING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1999027050-A1 | CLEAR OR TRANSLUCENT AQUEOUS FABRIC SOFTENER COMPOSITIONS CONTAINING HIGH ELECTROLYTE CONTENT AND OPTIONAL PHASE STABILIZER | THE PROCTER & GAMBLE COMPANY (US) | 1999-06-03 | — | — | WO | disclosed |
| WO-1998057721-A1 | PROCESS FOR IMPROVING THE ODOR OF COMMERCIAL SOLVENT USED IN FABRIC SOFTENING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1998-12-23 | — | — | WO | disclosed |
| EP-0828484-A1 | USE OF ARYL SUBSTITUTED CYCLOBUTYL ALKYL AMINES FOR THE TREATMENT OF OBESITY | Knoll AG (DE) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996038134-A1 | USE OF ARYL SUBSTITUTED CYCLOBUTYL ALKYL AMINES FOR THE TREATMENT OF OBESITY | KNOLL AG (DE) | 1996-12-05 | — | — | WO | disclosed |
| US-4814352-A | ANTIDEPRESSANT CYCLOBUTYL BENZYLAMINE | THE BOOTS COMPANY PLC (GB) | 1989-03-21 | — | — | US | disclosed |
| US-4806570-A | ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1989-02-21 | — | — | US | disclosed |
| US-4767790-A | ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1988-08-30 | — | — | US | disclosed |
| US-4746680-A | ANTIDEPRESSANTS | THE BOOTS COMPANY P.L.C. (GB) | 1988-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310500-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | SIGMAR1, OPRL1, SLC6A2 | SLC6A3 29/4885SLC6A4 6/4885SLC6A2 3/4885 |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | SLC6A3 2196/4885SLC6A4 2071/4885SLC6A2 1538/4885 |
| US-20070196421-A1 | Soft tissue implants and drug combination compositions, and use thereof | COL2A1, MMP1, FN1 | SLC6A3 2057/4885SLC6A4 3009/4885SLC6A2 2691/4885 |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | SLC6A3 2196/4885SLC6A4 2071/4885SLC6A2 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.